{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:42Z","timestamp":1790769342130,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":38,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_7","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:34:33Z","timestamp":1790764473000},"page":"123-136","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inotersen for the Treatment of Hereditary Transthyretin Amyloidosis"],"prefix":"10.1007","author":[{"given":"Maria","family":"Mahfouz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alishba","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"2","key":"7_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","volume":"128","author":"G Palladini","year":"2016","unstructured":"Palladini G, Merlini G (2016) What is new in diagnosis and management of light chain amyloidosis?. Blood 128(2):159\u2013168. https:\/\/doi.org\/10.1182\/blood-2016-01-629790","journal-title":"Blood"},{"issue":"9","key":"7_CR2","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp-2014-308724","volume":"86","author":"Y Sekijima","year":"2015","unstructured":"Sekijima Y (2015) Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86(9):1036\u20131043. https:\/\/doi.org\/10.1136\/jnnp-2014-308724","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7 Suppl","key":"7_CR3","first-page":"S107","volume":"23","author":"MA Gertz","year":"2017","unstructured":"Gertz MA (2017) Hereditary ATTR amyloidosis: burden of illness and diagnostic challenges. Am J Manag Care 23(7 Suppl):S107\u2013S112","journal-title":"Am J Manag Care"},{"issue":"21","key":"7_CR4","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1016\/j.jacc.2015.09.075","volume":"66","author":"MA Gertz","year":"2015","unstructured":"Gertz MA, Benson MD, Dyck PJ et al. (2015) Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol 66(21):2451\u20132466. https:\/\/doi.org\/10.1016\/j.jacc.2015.09.075","journal-title":"J Am Coll Cardiol"},{"key":"7_CR5","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.2147\/DDDT.S162913","volume":"13","author":"V Mathew","year":"2019","unstructured":"Mathew V, Wang AK (2019) Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis. Drug Des Devel Ther 13:1515\u20131525. https:\/\/doi.org\/10.2147\/DDDT.S162913","journal-title":"Drug Des Devel Ther"},{"issue":"21","key":"7_CR6","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1056\/NEJMc1810994","volume":"379","author":"JN Buxbaum","year":"2018","unstructured":"Buxbaum JN (2018) Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med 379(21):2086. https:\/\/doi.org\/10.1056\/NEJMc1810994","journal-title":"N Engl J Med"},{"issue":"2-3","key":"7_CR7","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jmb.2011.12.060","volume":"421","author":"SM Johnson","year":"2012","unstructured":"Johnson SM, Connelly S, Fearns C et al. (2012) The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 421(2-3):185\u2013203. https:\/\/doi.org\/10.1016\/j.jmb.2011.12.060","journal-title":"J Mol Biol"},{"issue":"1","key":"7_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al. (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"issue":"13","key":"7_CR9","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","volume":"78","author":"SJ Keam","year":"2018","unstructured":"Keam SJ (2018) Inotersen: first global approval. Drugs 78(13):1371\u20131376. https:\/\/doi.org\/10.1007\/s40265-018-0968-5","journal-title":"Drugs"},{"issue":"1","key":"7_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18553\/jmcp.2019.25.1.010","volume":"25","author":"K Mickle","year":"2019","unstructured":"Mickle K, Lasser KE, Hoch JS et al. (2019) The effectiveness and value of patisiran and inotersen for hereditary transthyretin amyloidosis. J Manag Care Spec Pharm 25(1):10\u201315. https:\/\/doi.org\/10.18553\/jmcp.2019.25.1.010","journal-title":"J Manag Care Spec Pharm"},{"key":"7_CR11","doi-asserted-by":"publisher","unstructured":"Gales L (2019) Tegsedi (Inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis. Pharmaceuticals (Basel) 12(2):1\u20136. https:\/\/doi.org\/10.3390\/ph12020078","DOI":"10.3390\/ph12020078"},{"issue":"1","key":"7_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-017-0948-5","volume":"17","author":"D Adams","year":"2017","unstructured":"Adams D, Suhr OB, Dyck PJ et al. (2017) Trial design and rationale for APOLLO, a phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. BMC Neurol 17(1):181. https:\/\/doi.org\/10.1186\/s12883-017-0948-5","journal-title":"BMC Neurol"},{"key":"7_CR13","unstructured":"Ionis Pharmaceuticals I (2023) WAINUA\u2122 (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis.\u2002https:\/\/ir.ionis.com\/news-releases\/news-release-details\/wainuatm-eplontersen-granted-regulatory-approval-us-treatment. Accessed 31 Dec 2025"},{"issue":"4","key":"7_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","volume":"84","author":"T Nie","year":"2024","unstructured":"Nie T (2024) Eplontersen: first approval. Drugs 84(4):473\u2013478. https:\/\/doi.org\/10.1007\/s40265-024-02008-5","journal-title":"Drugs"},{"key":"7_CR15","doi-asserted-by":"publisher","unstructured":"Al Shaer D, Al Musaimi O, Albericio F et al (2019) 2018 FDA Tides Harvest. Pharmaceuticals (Basel) 12(2):1\u20136. https:\/\/doi.org\/10.3390\/ph12020052","DOI":"10.3390\/ph12020052"},{"issue":"5","key":"7_CR16","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/nat.2020.0867","volume":"30","author":"RZ Yu","year":"2020","unstructured":"Yu RZ, Wang Y, Norris DA (2020) Immunogenicity assessment of inotersen, a 2\u2032-O-(2-methoxyethyl) antisense oligonucleotide in animals and humans: effect on pharmacokinetics, pharmacodynamics, and safety. Nucleic Acid Ther 30(5):265\u2013275. https:\/\/doi.org\/10.1089\/nat.2020.0867","journal-title":"Nucleic Acid Ther"},{"issue":"3","key":"7_CR17","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/13506129.2016.1191458","volume":"23","author":"EJ Ackermann","year":"2016","unstructured":"Ackermann EJ, Guo S, Benson MD et al. (2016) Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid 23(3):148\u2013157. https:\/\/doi.org\/10.1080\/13506129.2016.1191458","journal-title":"Amyloid"},{"issue":"5","key":"7_CR18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/mus.20503","volume":"33","author":"MD Benson","year":"2006","unstructured":"Benson MD, Kluve-Beckerman B, Zeldenrust SR et al. (2006) Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle Nerve 33(5):609\u2013618. https:\/\/doi.org\/10.1002\/mus.20503","journal-title":"Muscle Nerve"},{"issue":"4","key":"7_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13506129.2017.1374946","volume":"24","author":"MD Benson","year":"2017","unstructured":"Benson MD, Dasgupta NR, Rissing SM et al. (2017) Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy. Amyloid 24(4):219\u2013225. https:\/\/doi.org\/10.1080\/13506129.2017.1374946","journal-title":"Amyloid"},{"issue":"1","key":"7_CR20","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","volume":"27","author":"NR Dasgupta","year":"2020","unstructured":"Dasgupta NR, Rissing SM, Smith J et al. (2020) Inotersen therapy of transthyretin amyloid cardiomyopathy. Amyloid 27(1):52\u201358. https:\/\/doi.org\/10.1080\/13506129.2019.1685487","journal-title":"Amyloid"},{"issue":"1","key":"7_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al. (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"issue":"8","key":"7_CR22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/ene.14285","volume":"27","author":"TH Brannagan","year":"2020","unstructured":"Brannagan TH, Wang AK, Coelho T et al. (2020) Early data on long-term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2-year update from the open-label extension of the NEURO-TTR trial. Eur J Neurol 27(8):1374\u20131381. https:\/\/doi.org\/10.1111\/ene.14285","journal-title":"Eur J Neurol"},{"issue":"1","key":"7_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al. (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"issue":"4","key":"7_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/mus.27675","volume":"66","author":"C Karam","year":"2022","unstructured":"Karam C, Brown D, Yang M et al. (2022) Long-term treatment effects of inotersen on health-related quality of life in patients with hATTR amyloidosis with polyneuropathy: analysis of the open-label extension of the NEURO-TTR trial. Muscle Nerve 66(4):438\u2013446. https:\/\/doi.org\/10.1002\/mus.27675","journal-title":"Muscle Nerve"},{"key":"7_CR25","doi-asserted-by":"publisher","unstructured":"Yu RZ, Collins JW, Hall S et al. (2020) Population pharmacokinetic-pharmacodynamic modeling of inotersen, an antisense oligonucleotide for treatment of patients with hereditary transthyretin amyloidosis. Nucleic Acid Ther 30(3):153\u2013163. https:\/\/doi.org\/10.1089\/nat.2019.0822","DOI":"10.1089\/nat.2019.0822"},{"issue":"2","key":"7_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1517\/17425255.2013.737320","volume":"9","author":"RZ Yu","year":"2013","unstructured":"Yu RZ, Grundy JS, Geary RS (2013) Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol 9(2):169\u2013182. https:\/\/doi.org\/10.1517\/17425255.2013.737320","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"4","key":"7_CR27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1517\/17425250902877680","volume":"5","author":"RS Geary","year":"2009","unstructured":"Geary RS (2009) Antisense oligonucleotide pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 5(4):381\u2013391. https:\/\/doi.org\/10.1517\/17425250902877680","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"7_CR28","volume-title":"Pharmacoeconomic review report: Inotersen (Tegsedi): Indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR)","author":"Canadian Agency for Drugs and Techn","year":"2020","unstructured":"Canadian Agency for Drugs and Technologies in Health, 2020. Pharmacoeconomic review report: Inotersen (Tegsedi): Indication: stage I or II polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). Canadian Agency for Drugs and Technologies in Health, Ottawa, ON"},{"key":"7_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2199-8-57","volume":"8","author":"AM Adams","year":"2007","unstructured":"Adams AM, Harding PL, Iversen PL et al. (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 8: 57","journal-title":"BMC Mol Biol"},{"key":"7_CR30","unstructured":"ClinicalTrials.gov (2026) ION-682884 in Patients With TTR Amyloid Cardiomyopathy. https:\/\/clinicaltrials.gov\/study\/NCT04843020. Accessed 22 Aug 2026."},{"key":"7_CR31","unstructured":"ClinicalTrials.gov (2020)TEGSEDI Pregnancy Surveillance Program. https:\/\/clinicaltrials.gov\/study\/NCT04270058. Accessed 31 Dec 2025."},{"key":"7_CR32","unstructured":"ClinicalTrials.gov (2019) CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM). https:\/\/clinicaltrials.gov\/study\/NCT04136171. Accessed 31 Dec 2025"},{"issue":"16","key":"7_CR33","doi-asserted-by":"publisher","first-page":"4213","DOI":"10.1073\/pnas.1613203114","volume":"114","author":"Y Echigoya","year":"2017","unstructured":"Echigoya Y, Nakamura A, Nagata T et al. (2017) Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 114(16):4213\u20134218. https:\/\/doi.org\/10.1073\/pnas.1613203114","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"7_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1073\/pnas.0406700102","volume":"102","author":"QL Lu","year":"2005","unstructured":"Lu QL, Rabinowitz A, Chen YC et al. (2005) Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci U S A 102(1):198\u2013203. https:\/\/doi.org\/10.1073\/pnas.0406700102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7_CR35","doi-asserted-by":"publisher","unstructured":"Ezzat K, Aoki Y, Koo T et al (2015) Self-assembly into nanoparticles is essential for receptor mediated uptake of therapeutic antisense oligonucleotides. Nano Lett 15(7):4364\u20134373. https:\/\/doi.org\/10.1021\/acs.nanolett.5b00490","DOI":"10.1021\/acs.nanolett.5b00490"},{"issue":"10","key":"7_CR36","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1023\/A:1016260110049","volume":"12","author":"I Walker","year":"1995","unstructured":"Walker I, Irwin WJ, Akhtar S (1995) Improved cellular delivery of antisense oligonucleotides using transferrin receptor antibody-oligonucleotide conjugates. Pharm Res 12(10):1548\u20131553","journal-title":"Pharm Res"},{"key":"7_CR37","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1038\/mtna.2014.76","volume":"4","author":"Y Echigoya","year":"2015","unstructured":"Echigoya Y, Aoki Y, Miskew B et al. (2015) Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45-55 with a cocktail of vivo-morpholinos in mdx52 mice. Mol Ther Nucleic Acids 4:e225. https:\/\/doi.org\/10.1038\/mtna.2014.76","journal-title":"Mol Ther Nucleic Acids"},{"key":"7_CR38","doi-asserted-by":"publisher","unstructured":"Seth PP, Siwkowski A, Allerson CR et al. (2009) Short antisense oligonucleotides with novel 2\u2032-4\u2032 conformationally restricted nucleoside analogues show improved potency without increased toxicity in animals. J Med Chem 52(1):10\u201313. https:\/\/doi.org\/10.1021\/jm801294h","DOI":"10.1021\/jm801294h"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:03:12Z","timestamp":1790766192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":38,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}